PhII AFM13Comb.w/Allogenic AB-101 in Pts.w/Recurrent/RefractoryHodgkinLymph/CD30-Pos.PeriT-CellLymph

Cancer
Lauren C Pinter-Brown
Phase II, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Study Description

The purpose of this study is to learn about the effectiveness and safety of a new study drug called AFM13 when used in combination with a new cell therapy called AB-101. The study will also look at how the body processes this combination of drugs (called "pharmacokinetics"). Neither AFM13 nor AB-101 is currently approved for use by the United States Food and Drug Administration (FDA) because they are still being studied.

Eligibility

If you have recurrent (has come back) or refractory (did not respond to treatment) classical Hodgkin lymphoma or CD30-positive peripheral T-cell lymphoma (PTCL).

if you are at least 18 years old.

You cannot participate in this study if you are female who is pregnant or breastfeeding or planning to become pregnant.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.